Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Tumor Immunotherapy01:27

Tumor Immunotherapy

1.7K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
Esophageal Varices-II: Clinical Features and Management01:28

Esophageal Varices-II: Clinical Features and Management

359
Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
359
Cancer Therapies02:49

Cancer Therapies

9.8K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
9.8K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Durvalumab Plus Chemotherapy for Advanced Biliary Tract Cancer: A Post Hoc Analysis of the TOPAZ-1 Randomized Clinical Trial.

JAMA oncology·2026
Same author

Durvalumab with gemcitabine-based chemotherapy regimens in advanced biliary tract cancer: primary results from the phase IIIb TOURMALINE study.

Journal of hepatology·2026
Same author

A Serum lncRNA Signature Determines Oncogenic YAP Activity in Cancer Patients.

International journal of cancer·2026
Same author

Trends in the incidence and surgical treatment of hepatocellular carcinoma in Ontario.

Canadian journal of surgery. Journal canadien de chirurgie·2026
Same author

Nivolumab in combination with lenvatinib in unresectable hepatocellular carcinoma: The IKF-t006/IMMUNIB translational phase-2 study.

European journal of cancer (Oxford, England : 1990)·2026
Same author

Trial design and end points in hepatocellular carcinoma: an EASL-AASLD-ILCA consensus statement.

Nature reviews. Clinical oncology·2026

相关实验视频

Updated: Jan 13, 2026

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
06:38

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

9.4K

在先进的HCC中,在免疫治疗后导航二线治疗☆☆.

Arndt Vogel1,2,3, Anna Saborowski1, Lorenza Rimassa4,5

  • 1Department of Gastroenterology, Hepatology, Infectious Diseases and Endocrinology, Hannover Medical School, Carl-Neuberg-Straße 1, 30625 Hannover, Germany.

JHEP reports : innovation in hepatology
|January 8, 2026
PubMed
概括

肝细胞癌的全身治疗方法已经进步,但初始治疗后的最佳测序仍然不清楚. 本综述审查了当前的证据和新兴的二线和后期治疗策略.

关键词:
检查点抑制剂检查点抑制剂肝细胞癌是肝细胞癌.动脉内疗法 动脉内疗法当地区域疗法 当地区域疗法系统性疗法是一种全身疗法.铁氨酸激酶抑制剂 铁氨酸激酶抑制剂

更多相关视频

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

1.1K
A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
12:24

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

Published on: September 30, 2021

5.9K

相关实验视频

Last Updated: Jan 13, 2026

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
06:38

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

9.4K
Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

1.1K
A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
12:24

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

Published on: September 30, 2021

5.9K

科学领域:

  • 肝胆道癌症 肝胆道癌症
  • 医学瘤学 医学瘤学
  • 临床研究是临床研究.

背景情况:

  • 肝细胞癌 (HCC) 的全身治疗选择显著改善了生存结果.
  • 最近的进展主要集中在一线治疗上,为随后的治疗顺序制造挑战.
  • 对于二线和后一线的HCC疗法存在有限的对比比较.

研究的目的:

  • 审查目前对第二线和随后治疗的证据.在HCC.
  • 探索优化HCC治疗序列的关键考虑因素.
  • 突出HCC管理中的新兴策略.

主要方法:

  • 对关键的III期试验和II期研究的审查.
  • 分析后期数据和现实世界的证据.
  • 考虑临床实践因素和正在进行的研究.

主要成果:

  • 通过先进的全身疗法观察到生存和反应的显著改善.
  • 对二线HCC治疗的证据主要来自非比较性研究.
  • 治疗决策涉及将证据与患者特定因素整合起来.

结论:

  • 在HCC进展后,治疗的最佳顺序需要进一步调查.
  • 新兴策略,如免疫疗法延续和新型向药物,显示出有希望的结果.
  • 完善HCC的治疗场景需要持续的研究和证据生成.